MediGene Signs Veregen® Commercialization Agreement with SynCore Bio in Taiwan

MediGene AG /
MediGene Signs Veregen® Commercialization Agreement with SynCore Bio in Taiwan
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. Martinsried/Munich, May 18, 2011. The biotech company MediGene AG (Frankfurt,
Prime Standard) has signed an exclusive license and supply agreement with
SynCore Bio, a subsidiary of the Sinphar Group, for the commercialization and
marketing of Veregen(®) ointment in Taiwan for the treatment of genital warts.
MediGene will supply Sinphar with API, Sinphar will produce the drug in its
Taiwan manufacturing facilities and SynCore Bio will market and sell the
ointment in Taiwan. Financial details of the agreement were not disclosed.MediGene has already entered into several marketing partnerships for Veregen(®),
e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and
Switzerland, with Laboratoires Expanscience for France, and with a number of
other partners across Europe, America, and Asia. MediGene is planning to
continue this global licensing strategy.Veregen(®) is currently available on the US, German, and Austrian markets. A
second wave of marketing applications within the European mutual recognition
procedure is planned, with Germany serving as the reference state in this
process.Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment) for the topical
treatment of external genital warts is a concentrate of catechins with a complex
defined composition, extracted from green tea leaves. MediGene acquired the
basic rights to the active ingredient in Veregen(®) from the Canadian company
Epitome Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
successful preclinical and clinical development, as well as the approval
process. Patent protection has also been further upgraded by a number of
proprietary inventions. Sinecatechins 15 % ointment (Veregen(®)) is now also
recommended as a treatment option in the US Department of Health and Human
Services Center for Disease Control and Prevention's the Sexually Transmitted
Diseases Treatment Guidelines 2010 for the treatment of genital warts.Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd (Taiwan Stock Exchange,
Symbol: 1734),with subsidiaries in China and Canada, specializes in the sales
and marketing of pharmaceutical products and dietary supplements. It is also
involved in the research and development of botanical new drugs.  One project is
currently undergoing US FDA phase II trial and another project is in the process
of US FDA IND submission. Its manufacturing facilities are approved by the
Taiwanese FDA and Japan PMDA according to PIC/s GMP guidelines. Further
information can be obtained at: www.sinphar.com.SynCore Bio: Syncore Biotechnology Co., Ltd, a joint venture between Sinphar
Pharmaceutical Co., Ltd and the National Health Research Institute of Taiwan, is
focused on the development of new drugs. Currently, it has started a phase I
first-in-man trial on an anti-cancer new chemical entity. Another anti-cancer
NCE project is in the pre-IND stage.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene(®) and Veregen(®)() are registered trademarks of MediGene AG.
Polyphenon E(®)() is a trademark of Mitsui Norin Co., Ltd. These trademarks may
be owned or licensed in select locations only. - ends -MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. MediGene is the first
German biotech company to have revenues from marketed products. It has various
drug candidates in clinical development and possesses innovative platform
technologies. MediGene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases.Contact MediGene AGJulia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor@medigene.com
--- End of Message --- MediGene AG
Lochhamer Strasse 11 Martinsried / München GermanyWKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press release as pdf:
http://hugin.info/132073/R/1516613/452934.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MediGene AG via Thomson Reuters ONE[HUG#1516613]